Edwards Lifesciences Co. (NYSE:EW) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Edwards Lifesciences Co. (NYSE:EW) have received a consensus recommendation of “Hold” from the twenty-six brokerages that are covering the company, Marketbeat Ratings reports. Sixteen equities research analysts have rated the stock with a hold recommendation and ten have given a buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $75.67.

A number of equities analysts have recently weighed in on EW shares. Bank of America lowered Edwards Lifesciences from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $105.00 to $75.00 in a research note on Thursday, July 25th. Robert W. Baird dropped their target price on Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating for the company in a report on Friday, October 25th. Royal Bank of Canada decreased their price target on shares of Edwards Lifesciences from $85.00 to $75.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. Citigroup dropped their price objective on shares of Edwards Lifesciences from $83.00 to $77.00 and set a “buy” rating for the company in a research note on Tuesday, October 1st. Finally, Barclays decreased their target price on shares of Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating on the stock in a research report on Monday, September 9th.

Edwards Lifesciences Trading Up 0.4 %

NYSE EW opened at $70.20 on Wednesday. The company has a market cap of $41.40 billion, a PE ratio of 10.13, a PEG ratio of 3.81 and a beta of 1.12. Edwards Lifesciences has a 12 month low of $58.93 and a 12 month high of $96.12. The stock has a 50 day moving average of $67.59 and a 200-day moving average of $75.91. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.67. The business had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.57 billion. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. Edwards Lifesciences’s revenue was up 8.9% on a year-over-year basis. During the same period last year, the business posted $0.59 EPS. On average, equities research analysts anticipate that Edwards Lifesciences will post 2.57 EPS for the current fiscal year.

Insider Transactions at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $69.51, for a total transaction of $347,550.00. Following the transaction, the vice president now owns 46,936 shares in the company, valued at approximately $3,262,521.36. This represents a 9.63 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Larry L. Wood sold 25,000 shares of the business’s stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the sale, the insider now directly owns 198,526 shares of the company’s stock, valued at $13,084,848.66. The trade was a 11.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 40,000 shares of company stock valued at $2,657,000. Corporate insiders own 1.27% of the company’s stock.

Institutional Investors Weigh In On Edwards Lifesciences

Institutional investors have recently bought and sold shares of the stock. Teachers Retirement System of The State of Kentucky grew its position in Edwards Lifesciences by 43.5% in the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 138,755 shares of the medical research company’s stock worth $9,156,000 after purchasing an additional 42,059 shares in the last quarter. Toronto Dominion Bank grew its holdings in shares of Edwards Lifesciences by 1.4% in the third quarter. Toronto Dominion Bank now owns 300,280 shares of the medical research company’s stock valued at $19,815,000 after acquiring an additional 4,008 shares in the last quarter. Neo Ivy Capital Management purchased a new stake in shares of Edwards Lifesciences during the third quarter valued at approximately $726,000. Coldstream Capital Management Inc. lifted its holdings in Edwards Lifesciences by 14.9% during the third quarter. Coldstream Capital Management Inc. now owns 9,382 shares of the medical research company’s stock worth $620,000 after acquiring an additional 1,219 shares during the period. Finally, Geode Capital Management LLC increased its position in shares of Edwards Lifesciences by 2.2% during the 3rd quarter. Geode Capital Management LLC now owns 13,521,147 shares of the medical research company’s stock valued at $889,050,000 after purchasing an additional 284,918 shares during the last quarter. Institutional investors own 79.46% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.